Work

Figure S3 from AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer

Year: 2024

Type: other

Abstract: Olaparib and onvansertib treatment in vivo models demonstrate modest toxicity.

DOI: 10.1158/1535-7163.27142521

Authors: Mannan Nouri, Andreas Varkaris, Maya Ridinger, Susan L. Dalrymple, Christopher M. Dennehy, John T. Isaacs, David J. Einstein, W.N. Brennen, Steven P. Balk

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4403043497

Cites:

Cited by:

Related to: 10